China: Food, Drugs, Healthcare, Life Sciences

China's pharmaceutical and life sciences regulatory landscape underwent significant transformation in 2026, with major policy updates spanning drug approval processes, medical device quality standards, and healthcare facility management. The National Medical Products Administration introduced priority review pathways for chemical APIs and updated cosmetics registration requirements, while new medical device production standards took effect nationwide.

生物安全及人类遗传资源管理是医药企业开展研发、临床试验、生物制品生产及跨境科研合作时需要关注的重要合规领域。本文结合医药企业的主

China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato